Affiliation:
1. Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, 142001, India
Abstract
Abstract:
Cancer is the world's fifth-most significant cause of related death and the second most
commonly diagnosed malignancy among women and men. Some of its types, like brain cancer, colon
cancer, and breast cancer, are threatened and considered fatal. These cancers are more prevalent in
developed and underdeveloped countries. Still, doxorubicin is considered a gold standard drug and the
only molecule used in multiple types of cancer. However, the toxicity and biopharmaceutical hindrances
like poor solubility, poor permeability, and high in vivo fate of drug cause low systematic circulation.
The creation of a multifunctional nanocarrier for targeted medication delivery that can transport
and accumulate drugs at cancer sites should help to lessen the likelihood of side effects. These
nanocarriers improve the targetability of infected tissue and the therapeutic circulation of drugs. Hence,
the present review focused on the improved targetability of doxorubicin using different nanocarriers
and its possible outcomes in different types of cancer. Moreover, the prior art also discussed various
challenges and prospects of improved doxorubicin delivery and its therapeutic outcomes.
Publisher
Bentham Science Publishers Ltd.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献